Todos Medical is fueled by passion, innovation and Israel’s entrepreneurial spirit. The company’s founders established the company to generate real change in the way cancer is diagnosed today. Pairing years of dedication and novel research, Todos has developed the Total Biochemical Infrared Analysis (TBIA) technology underlying the tests for Breast, Colorectal, and Lung Cancer Screening. The company continues to attract the attention of senior industry leaders and partners to support these efforts.


Rami Zigdon brings with him strong experience leading technology companies. Prior to founding Todos Medical with Dr. Udi Zelig and Mr. Shmuel Melman, he served as the country manager for Hitachi Semiconductors and Renesas Technology. He also served as a manager at Scitex Corporation (presently a division of Kodak), and as the Chief Technology Officer of NI Medical. Mr. Zigdon has been recognized for his leadership in the development and implementation of effective product development strategies and FDA submissions.

Mr. Zigdon has served as our CEO since our inception in 2010 and was appointed as a director of our Company in May 2016. From May 2011 through June 2015, he also served as a director. From 2003 to 2009, Mr. Zigdon served as sales manager for Israel of Renesas Technology, a leading Japanese semiconductors corporation. Prior to this position, Mr. Zigdon served as the manager of Hitachi Semiconductors Israel and as embedded systems group manager at RDT. Mr. Zigdon has held various technical and management positions at Scitex (in Belgium), NI Medical and Spectronix.

Mr. Zigdon graduated with honors from the Hebrew University in Jerusalem and holds a Bachelor Degree of Science in Biology from the Hebrew University, a B.S. in Electrical Engineering from the Ben Gurion University of the Negev, Beer-Sheva, and a MBA from the Heriot-Watt University, Edinburgh.


Dr. Udi Zelig is the scientific founder of Todos Medical. He has spent over a decade as a researcher at Ben Gurion University investigating the use of infrared spectroscopic methods for medical diagnosis. Dr. Zelig’s research has been recognized and supported by the Israel Cancer Association and the Ministry of Health’s Office of the Chief Scientist and published in numerous medical and biophysics journals and conferences.

Dr. Zelig was our Chief Technology Officer as a non-employee from inception through December 2011 while employed by Crow Technologies. In January 2012, we entered into an employment agreement with Dr. Zelig for him to serve as our full-time Chief Technology Officer. Dr. Zelig is a biomedical engineer with research experience of more than a decade in the conducting and managing of in-vitro and clinical experiments. His main research field is applications of infrared spectroscopy for blood cancer detection and investigation of chemotherapeutic drugs influence on blood cells. Dr. Zelig is author of numerous scientific publications in leading journals for medicine and biophysics.

He holds a Bachelor Degree of Science in Nuclear Engineering, a Master of Science and Ph.D. in bio-medical engineering, all from the Ben-Gurion University of the Negev, Beer-Sheva.


Dr. Joseph Wee was appointed managing director of our Singapore operations in July 2016.  Dr. Wee has over 45 years of experience as productivity and business management consultant to SMEs, MNCs, Government Linked Companies and Government Agencies.  Dr. Wee has held senior management and directorship positions in over 20 companies, including 3 publicly listed companies.  Dr. Wee has also served as a member of Advisory Committees appointed by Government Agencies.

Contact Us


1 Hamada St. Rehovot 7670301 Israel

Contact Form


Name *

Email *

Company *

Phone *

Subject *

Message *